Multicenter prospective cohort study to investigate efficacy, quality of life and cost-effectiveness of obinutuzumab for untreated follicular lymphoma(PEACE-FL)
Not Applicable
- Conditions
- follicular lymphoma
- Registration Number
- JPRN-UMIN000038572
- Lead Sponsor
- Clinical Hematology Study Group of National Hospital Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
Patients judged by attending physicians to be inappropriate for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incremental cost- effectiveness ratio, ICER
- Secondary Outcome Measures
Name Time Method Overall survival, OS Progression free survival, PFS POD24 (Progression of disease within 24 months) Overall response rate, ORR Complete response rate, CRR Quality of life, QOL Cost